R&G Pharmastudies Co. Ltd. (301333)
Market Closed
11 Aug, 06:57
XSHE XSHE Primary ¥
62. 61
+4.61
+7.9483%
¥
5.43B Market Cap
- P/E Ratio
0.64% Div Yield
9.82M Volume
- Eps
¥ 58
Previous Close Want to track 301333 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
| Name | Time | Cons. EPS | Eps |
|---|---|---|---|
| | | - | 0.36 |
| | | - | 0.37 |
| | | - | - |
| | | - | 0.59 |
| | | - | 0.27 |
| | | - | 0.37 |
| | | - | 0.38 |
| | | - | 0.38 |
301333 Earnings Reports FAQ
What is the earnings per share (EPS) for 301333?
EPS data for 301333 is currently not available, as R&G Pharmastudies Co. Ltd has not reported recent earnings.
What is the company's earnings growth rate?
Over the past 1 years, the earnings growth rate has been approximately -5.68%, reflecting the 301333's performance and XSHE market conditions.
When is the next earnings release date?
R&G Pharmastudies Co. Ltd has not announced its next earnings release date.
What were the most recent quarterly earnings?
The most recent quarterly earnings for R&G Pharmastudies Co. Ltd are not available at this time.
What is the price-to-earnings (P/E) ratio?
There is no P/E ratio for 301333 at this time, as R&G Pharmastudies Co. Ltd has no recent EPS data to calculate it.
